Jump to content

MYCO-005

Add links
From Wikipedia, the free encyclopedia
(Redirected from MYCO005)
MYCO-005
Clinical data
Other namesMYCO005
Drug classSerotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen[1][2][3]

MYCO-005 is a serotonin 5-HT2A receptor agonist and psychedelic hallucinogen which is under development for the treatment of depressive disorders and anxiety disorders.[1][2][4][3][5]

It is a tryptamine derivative and an analogue of psilocin.[1][3] However, whereas psilocin and other tryptamines show high affinity for and potent activation of not only the serotonin 5-HT2A receptor but also the serotonin 5-HT2B receptor, MYCO-005 does not bind to this receptor.[1][3] Activation of the serotonin 5-HT2B receptor is known to induce the development of cardiac valvulopathy and has been a concern with regard to chronic microdosing of psychedelics.[6][7] Since MYCO-005 does not activate the serotonin 5-HT2B receptor, it is anticipated to be heart-safe and to be safer for use in the contexts of both macro- and microdosing than other psychedelics.[1][3][5]

As of February 2024, MYCO-005 is in the research stage of development for depressive disorders and anxiety disorders.[1] It is being developed by Mydecine.[1][2] The exact chemical structure of MYCO-005 does not yet seem to have been disclosed.[1] However, the compound was patented in 2023 and the specified patent specifically describes aza-substituted psilocin analogues.[5][8]

References

[edit]
  1. ^ a b c d e f g h "Research programme: second generation psilocin analogs". AdisInsight. 13 February 2024. Retrieved 1 November 2024. A family of psilocin analogs (MYCO 005) with heart-safe microdose enabling properties is being developed by Mydecine Innovations Group for the treatment of [...]
  2. ^ a b c "Delving into the Latest Updates on MYCO-005 with Synapse". Synapse. 1 November 2024. Retrieved 1 November 2024.
  3. ^ a b c d e "Mydecine Announces MYCO-005 Family of Improved Safety Microdose Novel Molecules". BioSpace. 16 February 2022. Retrieved 1 November 2024.
  4. ^ "MYCO-005 Drug Profile". Ozmosi. 26 October 2023. Retrieved 1 November 2024.
  5. ^ a b c Mydecine Innovations Group (18 December 2023). "Mydecine Innovations Group Receives Notice of Allowance from USPTO for its MYCO-005 Compound". Yahoo Finance. Retrieved 1 November 2024.
  6. ^ Tagen M, Mantuani D, van Heerden L, Holstein A, Klumpers LE, Knowles R (September 2023). "The risk of chronic psychedelic and MDMA microdosing for valvular heart disease". J Psychopharmacol. 37 (9): 876–890. doi:10.1177/02698811231190865. PMID 37572027.
  7. ^ Rouaud A, Calder AE, Hasler G (March 2024). "Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins". J Psychopharmacol. 38 (3): 217–224. doi:10.1177/02698811231225609. PMC 10944580. PMID 38214279.
  8. ^ "Novel Aza-Substituted Psilocin Analogs And Methods Of Synthesizing The Same". Google Patents. 1 May 2023. Retrieved 1 November 2024.
Retrieved from "https://en.wikipedia.org/w/index.php?title=MYCO-005&oldid=1254918023"